THERAPY DOSSIER · th-d82962f02fc9

Neurotrophin-3 (NT-3) encapsulated in biodegradable polymeric nanoparticles dispersed in a hyaluronan/methyl cellulose hydrogel

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26214190 ↗2014Reported benefit

Sustained delivery of bioactive neurotrophin-3 to the injured spinal cord.

RatSpinal cord injuryCompressionFemaleInjection into the intrathecal spaceAcute local delivery after the clip compression injury

Model: Thoracic clip compression spinal cord injury

A single intrathecal injection of the nanoparticle-hydrogel system gave sustained NT-3 release, with NT-3 diffusing ventrally through the cord and detectable for at least 28 days. NT-3 delivery produced significant axon growth with no effect on the astroglial response compared with vehicle and inju…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.68. Machine-extracted fields require source verification.

Loading the evidence…